Stockscreener 앱 받기
0.2852
0.97%
-0.0028
시간 외 거래:
.29
0.0048
+1.68%
전일 마감가:
$0.288
열려 있는:
$0.278
하루 거래량:
317.52K
Relative Volume:
0.29
시가총액:
$28.55M
수익:
$1.20M
순이익/손실:
$-5.34M
주가수익비율:
-4.6149
EPS:
-0.0618
순현금흐름:
$-6.27M
1주 성능:
+1.13%
1개월 성능:
-15.42%
6개월 성능:
-10.71%
1년 성능:
-15.35%
1일 변동 폭
$0.278
$0.2912
1주일 범위
$0.2742
$0.3033
52주 변동 폭
$0.242
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
명칭
IGC Pharma Inc
전화
301-983-0998
주소
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2852 | 28.83M | 1.20M | -5.34M | -6.27M | -0.0618 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
IGC Pharma Inc 주식(IGC)의 최신 뉴스
IGC Pharma Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Edge LowerTrading Community - Newser
IGC Stock Price, Quote & Chart | IGC PHARMA INC (NYSEARCA:IGC) - ChartMill
IGC Pharma earnings beat, revenue topped estimates By Investing.com - Investing.com Australia
IGC Pharma (IGC) Q1 2026 Earnings: $-0.02 EPS Surges Past $-0.02 EstimatesEstimate Revision Count - Newser
IGC Pharma (IGC) Delivers Q1 2026 Beat — EPS $-0.02 vs $-0.02 ExpectedForward EPS Estimate - Newser
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment - BioSpace
Drug trial for Alzheimer’s agitation reaches 80% enrollment at IGC Pharma - Stock Titan
IGC Pharma (IGC) Q1 2026 Earnings Surprise: EPS $-0.02, Up SignificantPopular Trader Picks - Newser
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - Voice of Alexandria
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference - Black Hills Pioneer
IGC Pharma, Inc. Common Stock (NY: IGC - The Chronicle-Journal
IGC Pharma (NYSE: IGC) deepens Alzheimer’s R&D amid tight cash and new loans - Stock Titan
IGC Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
IGC Unveils Tau-PET Biomarker Study for Alzheimer's at Global Ta - GuruFocus
IGC Pharma Presents Tau-PET Alzheimer’s Research - ACCESS Newswire
Decoding Tau Heterogeneity: IGC Pharma Presents Novel Biomarker Research at the 2026 Global Tau Conference - marketscreener.com
TradingKey - TradingKey
New Strong Buy Stocks for Oct. 24: IGC, ASM and More - MSN
New to The Street Broadcasts Show #752 on Bloomberg Television Featuring Graphene Manufacturing Group (OTCQX:GMGRF), T-REX Acquisition Corp (NASDAQ:TRXA), KITON, and Roadzen (NASDAQ:RDZN) - ChartMill
The key trends fueling IGC Pharma (IGC) growth potential (Institutional Selling) 2026-05-08Wall Street Picks - Newser
IGC Technical Analysis & ETF Price Forecast - Intellectia AI
IGC Should I Buy - Intellectia AI
MSN Money - MSN
Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification - marketscreener.com
Cannabinoid Clinical Trials See Significant Growth for New… - Hemp Gazette
Cannabinoid Clinical Trials Gain Momentum: 50+ Companies Le… - Hemp Gazette
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase - BioSpace
As Alzheimer’s trial nears completion, IGC turns to caregivers - Stock Titan
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global - Scott Coop
Analysts Are Bullish on Top Healthcare Stocks: IGC Pharma (IGC), 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion - itemonline.com
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia - Times Argus
IGC Pharma Inc. (IGC) posts narrower than expected Q1 2026 loss, reports 5.5 percent year over year revenue decline.Crowd Sentiment Stocks - UBND thành phố Hải Phòng
IGC Pharma (IGC) Stock: Why Competitive Advantage (Slight Downtick) 2026-04-22Reversal Picks - Cổng thông tin điện tử tỉnh Lào Cai
ETFs Investing in IGC Pharma, Inc. Stocks - TradingView
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA - GuruFocus
IGC Expands Clinical Trials with New Site in Dallas - GuruFocus
IGC Pharma Secures New Promissory Note Financing Agreements - The Globe and Mail
IGC Pharma (IGC) Stock: Risk vs Reward (Underperforming) 2026-04-20Wall Street Picks - Xã Châu Thành
IGC Pharma Adds $514,000 in 12% Notes From FirstFire and Vanquish Funding - TradingView
IGC Pharma Inc (IGC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):